Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Other Non-Current Liabilities (2022 - 2025)

Axsome Therapeutics' Other Non-Current Liabilities history spans 4 years, with the latest figure at $77.5 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 15.42% year-over-year to $77.5 million; the TTM value through Dec 2025 reached $77.5 million, down 15.42%, while the annual FY2025 figure was $77.5 million, 15.42% down from the prior year.
  • Other Non-Current Liabilities for Q4 2025 was $77.5 million at Axsome Therapeutics, down from $89.9 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $91.7 million in Q4 2024 and bottomed at $27.4 million in Q3 2022.
  • The 4-year median for Other Non-Current Liabilities is $70.0 million (2024), against an average of $60.5 million.
  • The largest annual shift saw Other Non-Current Liabilities surged 163.01% in 2024 before it fell 15.42% in 2025.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $31.1 million in 2022, then surged by 135.69% to $73.3 million in 2023, then increased by 25.08% to $91.7 million in 2024, then dropped by 15.42% to $77.5 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Other Non-Current Liabilities are $77.5 million (Q4 2025), $89.9 million (Q3 2025), and $79.7 million (Q2 2025).